Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: A case report

Surgery is the preferred treatment for basal cell carcinoma (BCC), locally advanced or metastatic BCC, radiation therapy or systemic therapy can be considered. Programmed death receptor 1 (PD-1) inhibitors are rarely used to treat cutaneous BCC. In the present case, we found that tislelizumab, a PD-...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Ming-Jun, Chen, Yu-Chun, Cui, Xiao-Li, Yang, Qian, Xue, Qing-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
4200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174383/
https://www.ncbi.nlm.nih.gov/pubmed/37171300
http://dx.doi.org/10.1097/MD.0000000000033788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174383/
https://www.ncbi.nlm.nih.gov/pubmed/37171300
http://dx.doi.org/10.1097/MD.0000000000033788

Ejemplares similares